Dimethyl-(9H-purin-6-yl)-amine

ID: ALA407391

Cas Number: 938-55-6

PubChem CID: 3134

Product Number: D131565, Order Now?

Max Phase: Preclinical

Molecular Formula: C7H9N5

Molecular Weight: 163.18

Molecule Type: Small molecule

Names and Identifiers

Synonyms: 6-Dimethylaminopurine | Dimethyladenine | 6-dimethylaminopurine|938-55-6|N,N-dimethyl-7H-purin-6-amine|6-(Dimethylamino)purine|N,N-Dimethyladenine|N6,N6-Dimethyladenine|6-Dimethyladenine|N(6),N(6)-Dimethyladenine|Dimethyladenine|1H-Purin-6-amine, N,N-dimethyl-|Adenine, N,N-dimethyl-|N,N-Dimethyl-9H-purin-6-amine|6,6-Dimethyladenine|N,N-Dimethyl-6-aminopurine|6-DMAP|Adenine, N6,N6-dimethyl-|Purine, 6-(dimethylamino)-|NSC 401568|N(6)-dimethyladenine|CHEBI:60281|6-Dimethylamino-9H-purine|649SA4S2CVShow More⌵

Canonical SMILES:  CN(C)c1ncnc2nc[nH]c12

Standard InChI:  InChI=1S/C7H9N5/c1-12(2)7-5-6(9-3-8-5)10-4-11-7/h3-4H,1-2H3,(H,8,9,10,11)

Standard InChI Key:  BVIAOQMSVZHOJM-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 12 13  0  0  0  0  0  0  0  0999 V2000
    0.3833   -0.3612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3312    0.0513    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3312    0.8763    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0977    0.8763    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6008    0.4638    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0977   -1.5987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3312   -1.5987    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3833   -1.1862    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0977    0.0513    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3833    1.2888    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1158    1.1312    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1158   -0.2036    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  1  8  1  0
  1  9  1  0
  2  3  1  0
  2 12  1  0
  3 10  2  0
  3 11  1  0
  4  9  2  0
  4 10  1  0
  5 11  2  0
  5 12  1  0
  6  8  1  0
  7  8  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA407391

   6-(Dimethylamino)purine

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 163.18

Molecular Weight (Monoisotopic): 163.0858

AlogP: 0.42

#Rotatable Bonds: 1

Polar Surface Area: 57.70

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 10.19

CX Basic pKa: 3.38

CX LogP: 0.36

CX LogD: 0.36

Aromatic Rings: 2

Heavy Atoms: 12

QED Weighted: 0.66

Np Likeness Score: -1.05

References

1. Kelley JL, McLean EW, Ferris RM, Howard JL..  (1989)  Benzodiazepine receptor binding activity of 6,9-disubstituted purines.,  32  (5): [PMID:2540330] [10.1021/jm00125a015]

2. Young RC, Jones M, Milliner KJ, Rana KK, Ward JG..  (1990)  Purine derivatives as competitive inhibitors of human erythrocyte membrane phosphatidylinositol 4-kinase.,  33  (8): [PMID:2165159] [10.1021/jm00170a005]

3. Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S..  (2007)  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.,  104  (51): [PMID:18077363] [10.1073/pnas.0708800104]

4. Okamoto M, Saito N, Kojima H, Okabe T, Takeda K, Ichijo H, Furuya T, Nagano T..  (2011)  Identification of novel ASK1 inhibitors using virtual screening.,  19  (1): [PMID:21134755] [10.1016/j.bmc.2010.11.004]

5. PubChem BioAssay data set, 

6. Anderson PC, De Sapio V, Turner KB, Elmer SP, Roe DC, Schoeniger JS..  (2012)  Identification of binding specificity-determining features in protein families.,  55  (5): [PMID:22289061] [10.1021/jm200979x]

7. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

8. Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN, Schwaller J, Sundström M, Knapp S..  (2007)  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.,  104  (51): [PMID:18077363] [10.1073/pnas.0708800104]

9. Simon Townson and Suzanne Gokool. GlaxoSmithKline Published Kinase Inhibitor Set 2 Onchocerca lienalis Screening Data,  [10.6019/CHEMBL3988181]

10. Bancet A,Raingeval C,Lomberget T,Le Borgne M,Guichou JF,Krimm I.  (2020)  Fragment Linking Strategies for Structure-Based Drug Design.,  63  (20.0): [PMID:32539387] [10.1021/acs.jmedchem.0c00242]

11. Williamson DS, Smith GP, Mikkelsen GK, Jensen T, Acheson-Dossang P, Badolo L, Bedford ST, Chell V, Chen IJ, Dokurno P, Hentzer M, Newland S, Ray SC, Shaw T, Surgenor AE, Terry L, Wang Y, Christensen KV..  (2021)  Design and Synthesis of Pyrrolo[2,3-d]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate.,  64  (14.0): [PMID:34184879] [10.1021/acs.jmedchem.1c00720]

Source

Source(4):

• Scientific Literature
• PubChem BioAssays
• AstraZeneca Deposited Data
• Published Kinase Inhibitor Set 2